The independent platform for news, articles and advice for professionals in laboratory medicine

Improving accessibility of gestational diabetes screening for Hampshire’s expectant mothers

Digital clinical diagnostics and diabetes home-testing provider Digostics has revealed the results from its ground-breaking gestational diabetes mellitus (GDM) remote screening collaboration with University Hospital Southampton NHS Foundation Trust (UHS), a partnership that saw expectant mothers in Hampshire become the first globally to access an oral-glucose tolerance test (OGTT) without needing to attend clinic.

The initiative, first announced in April 2023, saw women assessed as at risk of developing GDM by their midwife issued with a GTT@home test kit from Digostics to undertake their OGTT at home. The service’s introduction saw all women successfully tested in their target test week. Furthermore, 100% of mothers and maternity staff who responded to user surveys recommended GTT@home over traditional clinic testing.

The implementation of GTT@home stemmed from an ambition by UHS to improve the quality of the test and to test in a more patient-focused way. Additionally, to enable testing to be undertaken more quickly so that treatment can be initiated sooner where required. Objectives also included reducing the number of antenatal appointments required, freeing up valuable resources and improving healthcare equity of access, particularly for at-risk patient groups.

Up to 20% of UK pregnancies are impacted by GDM, with background risk factors including age, ethnicity and body mass index. Undiagnosed or untreated, GDM can lead to pregnancy complications that warrant unscheduled or even emergency changes to the birth-plan to protect both mother and baby. GDM also confers an increased risk for both mother³ and child† of developing Type 2 diabetes later in life and accurate diagnosis with a reliable test is therefore important.

Prior to the implementation of GTT@home, undertaking an OGTT would require women to travel, while fasted, to a dedicated clinic on a specific date and spend over two hours at the hospital.  The inconvenience the in-clinic test represents, especially for example for those with childcare pressures, means missed appointments and late tests are frequent.

“The contribution GTT@home has made to improving OGTT test patient empowerment, equity and accuracy will enable improved care for our patients when GDM is suspected and detected,” said Dr Matthew Coleman, Consultant Obstetric Physician at UHS.  “In equal parts, we are excited that this revolutionary new at-home test is going to dramatically change the way we deliver GDM testing during antenatal care.”

In a significant improvement from the in-clinic workflow, which typically sees blood samples only sent to the laboratory for analysis once the final test of the day has been completed, GTT@home ensures both blood tests associated with the OGTT – the initial fasting test and the two-hour test after consumption of a glucose drink – are analysed immediately at the point of testing. This eliminates the sample degradation that can occur between in-clinic blood sampling and laboratory analysis with the traditional OGTT.

After completing a test with GTT@home, the user can send their test data directly to their antenatal care team with a simple scan of a snap-off fob attached to the innovative test device using the GTT@home mobile app and the near field communication (NFC) functionality within their smartphone.  Although users can send their test data via a prepaid envelope in the test kit, 98% elected to send their data via their smartphone, with their results available for review by their midwife much faster than could be achieved via the hospital laboratory.

“UHS’ pilot implementation of GTT@home has shown that OGTT home testing is not just a viable alternative to in-clinic testing but a significantly more accessible way to screen women for diabetes and potentially improve test accuracy,” said Professor Richard Holt, Professor in Diabetes and Endocrinology, University of Southampton.

After the successful pilot of GTT@home at UHS, NHS trusts and health boards nationwide are looking to introduce GTT@home for their pregnant women in 2024.  UK-headquartered Digostics is also setting up operations in the Middle East and Asia Pacific to meet the significant demand for GTT@home in these regions and aims to expand to Europe and the USA.

 

Upcoming Events

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025